Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

Zurück
24 April 2018, 08:00
2148

Cipla plans to approve a drug Q-TIB in South Africa for the treatment of tuberculosis in HIV-positive people

Cipla plans to approve a drug Q-TIB in South Africa for the treatment of tuberculosis in HIV-positive people - Bild 1

The pharmaceutical company Cipla announced its intention to approve in South Africa a drug Q-TIB, intended for the treatment of co-infection of tuberculosis in people living with HIV. According to the company, Q-TIB is a 3-in-1 combination of co-trimoxazole, isoniazid and vitamin B6 at a fixed dosage.

Dr. Nic de Jongh, Chief Scientific Officer at Cipla, told reporters that the new drug combines the WHO recommended and effective low-cost anti-tuberculosis therapy, including the antibacterial co-trimoxazole (includes sulfamethoxazole and trimethoprim), isoniazid and vitamin B6, allowing prevention of side effects associated with isoniazid.

According to Dr. de Jong, the combined Q-TIB will significantly increase adherence to treatment among HIV-positive patients with tuberculosis and improve their quality of life.

According to WHO, in 2017 in South Africa, more than 100 thousand deaths of people living with HIV and tuberculosis were registered. This is almost 70% more than among those who did not have the virus. At the same time, experts believe, in about 59% of cases the cause of tuberculosis was HIV infection.

 

Autor: Ivan Shangin

Teilen Sie in sozialen Netzwerken